{"id":5360,"date":"2024-12-17T00:27:57","date_gmt":"2024-12-17T00:27:57","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=rkd-news&#038;p=5360"},"modified":"2025-10-14T13:09:21","modified_gmt":"2025-10-14T13:09:21","slug":"uscd163-inflammatory-biomarker-spartan-interim","status":"publish","type":"rkd-news","link":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/","title":{"rendered":"Exploring the Mechanism of Sparsentan in IgAN: Including a Spotlight on Urinary sCD163, a Key Marker of Inflammation"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header.png\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Exploring the Mechanism of Sparsentan in IgAN: Including a Spotlight on Urinary sCD163, a Key Marker of Inflammation<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\r\n\t<section style=\"padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-top:calc(-120px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\"><\/i> Published on April 17, 2025\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\n\t\t<div class=\"info-block-box\">\n\t\t\t\n\t\t\t\t\t<\/div>\n\n\t\t\n\t\t<div class=\"info-block-share\">Share:\n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fuscd163-inflammatory-biomarker-spartan-interim%2F&#038;text=Exploring+the+Mechanism+of+Sparsentan+in+IgAN%3A+Including+a+Spotlight+on+Urinary+sCD163%2C+a+Key+Marker+of+Inflammation\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fuscd163-inflammatory-biomarker-spartan-interim%2F&#038;title=Exploring+the+Mechanism+of+Sparsentan+in+IgAN%3A+Including+a+Spotlight+on+Urinary+sCD163%2C+a+Key+Marker+of+Inflammation\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fuscd163-inflammatory-biomarker-spartan-interim%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Exploring%20the%20Mechanism%20of%20Sparsentan%20in%20IgAN%3A%20Including%20a%20Spotlight%20on%20Urinary%20sCD163%2C%20a%20Key%20Marker%20of%20Inflammation&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fuscd163-inflammatory-biomarker-spartan-interim%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div class=\"modal modal-request-copy\" style=\"display: none;\" id=\"modal-request-copy\">\n\t<div class=\"modal__backdrop\">\n\t\t<div class=\"modal__card\">\n\t\t\t<button class=\"modal__close btn-close\" aria-label=\"Close modal\">&times;<\/button>\n\t\t\t<h4 class=\"has-heading-3-font-size\">Request a copy<\/h4>\n\t\t\t\n<div class=\"wpcf7 no-js\" id=\"wpcf7-f2317-o1\" lang=\"en-US\" dir=\"ltr\" data-wpcf7-id=\"2317\">\n<div class=\"screen-reader-response\"><p role=\"status\" aria-live=\"polite\" aria-atomic=\"true\"><\/p> <ul><\/ul><\/div>\n<form action=\"\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/5360#wpcf7-f2317-o1\" method=\"post\" class=\"wpcf7-form init wpcf7-acceptance-as-validation\" aria-label=\"Contact form\" novalidate=\"novalidate\" data-status=\"init\">\n<fieldset class=\"hidden-fields-container\"><input type=\"hidden\" name=\"_wpcf7\" value=\"2317\" \/><input type=\"hidden\" name=\"_wpcf7_version\" value=\"6.1.1\" \/><input type=\"hidden\" name=\"_wpcf7_locale\" value=\"en_US\" \/><input type=\"hidden\" name=\"_wpcf7_unit_tag\" value=\"wpcf7-f2317-o1\" \/><input type=\"hidden\" name=\"_wpcf7_container_post\" value=\"0\" \/><input type=\"hidden\" name=\"_wpcf7_posted_data_hash\" value=\"\" \/>\n<\/fieldset>\n<div class=\"cf7-fields-wrapper\">\n  <div class=\"form-two-cols\">\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-first-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-first-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"First Name*\" value=\"\" type=\"text\" name=\"request-first-name\" \/><\/span>\n    <\/div>\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-last-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-last-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Last Name*\" value=\"\" type=\"text\" name=\"request-last-name\" \/><\/span>\n    <\/div>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-your-email\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-validates-as-required wpcf7-text wpcf7-validates-as-email\" id=\"request-your-email\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Email*\" value=\"\" type=\"email\" name=\"request-your-email\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-title\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Title*\" value=\"\" type=\"text\" name=\"request-title\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-agree\"><span class=\"wpcf7-form-control wpcf7-acceptance\"><span class=\"wpcf7-list-item\"><label><input type=\"checkbox\" name=\"request-agree\" value=\"1\" class=\"required\" id=\"request-agree\" aria-invalid=\"false\" \/><span class=\"wpcf7-list-item-label\">All personal data will be processed by or on behalf of Travere to provide access to company information and to respond to requests. Travere will retain personal data only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal data is private and will not disseminate it to third parties who are not providing services to Travere. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\">Travere privacy policies<\/a>.<\/span><\/label><\/span><\/span><\/span>\n  <\/div>\n  <div class=\"form-group text-right\">\n    <input class=\"wpcf7-form-control wpcf7-submit has-spinner btn\" id=\"request-submit\" type=\"submit\" value=\"Yes, continue\" \/>\n  <\/div>\n<\/div><div class=\"wpcf7-response-output\" aria-hidden=\"true\"><\/div>\n<\/form>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div> <\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">In this issue we:<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li><span style=\"color: #003366;\"><a style=\"color: #003366;\" href=\"#h-angiotensin-ii-ang-ii-and-endothelin-1-et-1-contribute-to-inflammation-in-iga-nephropathy-1\">Discuss the importance of targeting inflammation in IgA nephropathy by inhibition of endothelin-1 (ET-1) and angiotensin II<\/a><\/span><\/li>\n<li><span style=\"color: #003366;\"><a style=\"color: #003366;\" href=\"#h-measuring-inflammation-biomarkers-in-iga-nephropathy-can-provide-insight-into-disease-progression-severity-remission-and-treatment-response-12-14\">Learn how the urinary soluble CD163 (u-sCD163) inflammatory biomarker can measure IgA nephropathy progression, severity, and remission<\/a><\/span><\/li>\n<li><span style=\"color: #003366;\"><a style=\"color: #003366;\" href=\"#h-biomarker-data-from-spartan-interim-analysis-demonstrated-the-anti-inflammatory-effect-of-sparsentan-which-was-previously-only-seen-in-mouse-models-1-8-19-22\">Highlight data from the interim analysis of the Phase 2 SPARTAN study demonstrating the anti-inflammatory effect of sparsentan<\/a><\/span><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"event-video\" id=\"video\">\n\t\t\t<p class=\"has-heading-3-font-size\">Welcome by Prof. Si\u00e2n Griffin<\/p>\n\t\t\n\t<a href=\"#\" class=\"event-video--img\" style=\"background-image: url('https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-KOL-video_sian.png');\">\n\t\t<span class=\"icon2-play\" aria-hidden=\"true\"><\/span>\n\t<\/a>\n\t\n\t<div class=\"event-video--vimeo\"><\/div>\n\t\n\t<\/div>\n\n<script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script>\n<script>\n\tdocument.addEventListener(\"DOMContentLoaded\", function() {\n\t\tconst imgLink = document.querySelector(\".event-video--img\");\n\t\tconst vimeoDiv = document.querySelector(\".event-video--vimeo\");\n\t\tlet iframeExists = false;\n\t\tlet player;\n\n\t\timgLink.addEventListener(\"click\", function(event) {\n\t\t\tevent.preventDefault();\n\n\t\t\tif (!iframeExists) {\n\t\t\t\tconst iframe = document.createElement(\"iframe\");\n\t\t\t\tiframe.src = \"https:\/\/player.vimeo.com\/video\/1067907566\";\n\t\t\t\tiframe.frameBorder = \"0\";\n\t\t\t\tiframe.allow = \"autoplay; fullscreen\";\n\t\t\t\tiframe.allowFullscreen = true;\n\t\t\t\tvimeoDiv.appendChild(iframe);\n\t\t\t\t\n\t\t\t\tplayer = new Vimeo.Player(iframe);\n\t\t\t\tplayer.play();\n\t\t\t\tiframeExists = true;\n\t\t\t}\n\n\t\t\tvimeoDiv.style.display = \"block\";\n\t\t\timgLink.style.display = \"none\";\n\t\t});\n\n\t\tvimeoDiv.addEventListener(\"click\", function() {\n\t\t\tconst iframe = vimeoDiv.querySelector(\"iframe\");\n\t\t\tiframe.contentWindow.postMessage('{\"method\":\"play\"}', 'https:\/\/player.vimeo.com\/video\/1067907566');\n\t\t});\n\t});\n<\/script>\n\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-angiotensin-ii-ang-ii-and-endothelin-1-et-1-contribute-to-inflammation-in-iga-nephropathy-1\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Angiotensin II (Ang II) and endothelin-1 (ET-1) contribute to inflammation in IgA nephropathy<sup>1<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p><a href=\"https:\/\/clleancode.top\/travere-redesign\/episode\/role-of-endothelin-in-igan\/\" target=\"_blank\" rel=\"noopener\">Ang II and ET-1 are key disease mediators<\/a>\u00a0that contribute to the progression of IgA nephropathy.<sup>1<\/sup>\u00a0They upregulate each other and exert an additive effect driving ongoing kidney damage.<sup>1-3<\/sup><\/p>\n<p>Ang II impacts nearly the entire kidney through activation of angiotensin II subtype 1 receptors (AT<sub>1<\/sub>R), and ET-1 activity in the kidney is mostly mediated through the endothelin type A receptor (ET<sub>A<\/sub>R).<sup>1<\/sup><\/p>\n<p>Both Ang II and ET-1 have similar pathophysiological functions within the kidney that contribute to actions such as vasoconstriction, inflammation, and cellular proliferation.<sup>1,4,5<\/sup>\u00a0Collectively, these effects contribute to hypertension, glomerulosclerosis, proteinuria, and tubulointerstitial fibrosis.<sup>1,4,6<\/sup><\/p>\n<p>Preclinical data suggest that increased ET-1 leads to inflammation, particularly in the glomerulus.<sup>7-10<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div class=\"wp-block-group is-style-text-content is-layout-constrained wp-block-group-is-layout-constrained\">\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"\/>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"podcast-categories\">\n\t\t<div class=\"podcast-category\">\n\t\t<div class=\"podcast-category-img\">\n\t\t\t<img decoding=\"async\" width=\"2560\" height=\"2560\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-300x300.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-1024x1024.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-150x150.webp 150w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-768x768.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-1536x1536.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-2048x2048.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/06\/Ep-3-graphic-290x290.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t<\/div>\n\t\t<div class=\"podcast-category-content\">\n\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<p class=\"has-heading-4-font-size\"><br \/><strong>Rare Kidney Disease Show Podcast<\/strong><\/p>\n\t\t\t<p>Learn more about the endothelin system and how it relates to IgAN pathophysiology<\/p>\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/episode\/role-of-endothelin-in-igan\/\" class=\"btn\" aria-label=\"Listen now\">Listen now<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"\/>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Within the glomerulus, ET-1 is constitutively expressed in all cells and is involved in the homeostasis of glomerular structure and filtration function.<sup>7<\/sup> Findings indicate that ET-1 increases glomerular permeability to proteins and renal inflammation.<sup>7-10<\/sup><\/p>\n<p><strong>\u2022 Mesangial cells:\u00a0<\/strong>Increased ET-1 causes cellular proliferation, contraction, and increased extracellular matrix accumulation.<sup>7,10<\/sup> Excessive ET-1 activity in mesangial cells may be strongly indicative of glomerular damage.<sup>10<\/sup><\/p>\n<p><strong>\u2022 Endothelial cells and podocytes: <\/strong>Increased ET-1 production leads to glomerular inflammation and injury, sclerosis, and podocyte injury, all contributing to proteinuria.<sup>7<\/sup><\/p>\n<p><strong>\u2022 Glycocalyx:<\/strong> The IgA nephropathy-prone gddY mouse model demonstrated an upregulation of ET-1 and ET<sub>A<\/sub>R and a decrease in the glycocalyx area.<sup>8<\/sup><\/p>\n<p>Ultimately blocking ET<sub>A<\/sub>R could mediate glomerular damage and the proinflammatory effects of ET-1.<sup>7-9<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"8211\" height=\"6666\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image.png 8211w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image-300x244.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image-1024x831.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image-768x623.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image-1536x1247.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/renal-ET1-ETAR-march-newsletter_image-290x235.webp 290w\" sizes=\"auto, (max-width: 8211px) 100vw, 8211px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p style=\"text-align: left;\">Figure. Renal ET-1 and ET<sub>A<\/sub>R increases in IgA nephropathy<sup>11<\/sup><\/p><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-measuring-inflammation-biomarkers-in-iga-nephropathy-can-provide-insight-into-disease-progression-severity-remission-and-treatment-response-12-14\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Measuring inflammation biomarkers in IgA nephropathy can provide insight into disease progression, severity, remission, and treatment response<sup>12-14<\/sup><\/mark><\/span><\/h3>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Several biomarkers have been associated with inflammation in IgA nephropathy including urinary soluble CD163 (u-sCD163).<sup>12,15,16<\/sup><\/p>\n<p>CD163 is a transmembrane protein expressed during the healing phase of inflammation.<sup>12<\/sup> It is a marker of alternatively activated macrophages and inflammation in several proinflammatory diseases.<sup>13,17,18<\/sup><\/p>\n<p>In the kidney, CD163 has been correlated with macrophage infiltration and is associated with active lesions.<sup>15<\/sup><\/p>\n<p>In IgA nephropathy, u-sCD163 has been associated with inflammation in the TESTING and NEFIGAN studies.<sup>15,16<\/sup><\/p>\n<p>The recent Phase 2 SPARTAN interim analysis, presented at <a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/asn-kidney-week-2024\/\">ASN Kidney Week 2024<\/a> and <a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/wcn-2025\/\">WCN 2025<\/a>, assessed u-sCD163 as an inflammation biomarker in patients with IgA nephropathy treated with sparsentan.<sup>19<\/sup><!-- wp:spacer {\"height\":\"30px\"} --><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-biomarker-data-from-spartan-interim-analysis-demonstrated-the-anti-inflammatory-effect-of-sparsentan-which-was-previously-only-seen-in-mouse-models-1-8-19-22\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Biomarker data from SPARTAN interim analysis demonstrated the anti-inflammatory effect of sparsentan, which was previously only seen in mouse models<sup>1,8,19-22<\/sup><\/span><\/mark><\/h4>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Early mouse models of IgA nephropathy found that sparsentan decreased glomerular macrophage infiltration and attenuated immune-complex mediated mesangial cellularity.<sup>21,22<\/sup> Recent IgA nephropathy mouse models have demonstrated that treatment with sparsentan <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-ameliorates-glomerular-hypercellularity-and-inflammatory-gene-networks-iga-nephropathy-mouse-model\/\">can attenuate gene expression specific to immune and inflammatory pathways<\/a>, including <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-losartan-iga-nephropathy-gddy-mouse-model\/\">inflammatory pathway gene markers<\/a>.<sup>8,20<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1971\" height=\"1343\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image.png 1971w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image-300x204.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image-1024x698.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image-768x523.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image-1536x1047.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/impact-of-sparsentan-kidneys_image-290x198.webp 290w\" sizes=\"auto, (max-width: 1971px) 100vw, 1971px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p style=\"text-align: left;\">Figure. Sparsentan decreased expression of immune and pro-inflammatory signaling in kidneys of IgA nephropathy-prone gddY mice<sup>8<\/sup><\/p><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Interim <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/spartan-igan-first-line-interim-analysis\/\">u-sCD163 data from SPARTAN<\/a> (n=11), a Phase 2, open-label, single-arm multicenter trial, demonstrated the anti-inflammatory effect of sparsentan.<sup>19<\/sup><\/p>\n<p>Findings showed a rapid and sustained reduction of u-sCD163 with sparsentan treatment.<sup>19<\/sup>\u00a0At Week 24, there was a 50% reduction in u-sCD163 from baseline indicating a reduction in inflammation in patients.<sup>19<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"8211\" height=\"5593\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image.png 8211w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image-300x204.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image-1024x698.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image-768x523.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image-1536x1046.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image-2048x1395.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/spartan-interim-analysis_image-290x198.webp 290w\" sizes=\"auto, (max-width: 8211px) 100vw, 8211px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p style=\"text-align: left;\">Figure. u-sCD163 levels decreased over 24 weeks with sparsentan<sup>19<\/sup><\/p><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>The SPARTAN study will continue to evaluate additional biomarkers to better elucidate the additional <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protective-mechanism-sparsentan-chronic-kidney-disease-models\/\">mechanistic actions of sparsentan<\/a>, a novel, non-immunosuppressive Dual Endothelin Angiotensin Receptor Antagonist (DEARA).<sup>1,19,23<\/sup><\/p>\n<p>Over the last two decades, preclinical data has implicated ET-1 in renal inflammation.<sup>7,9,10<\/sup> Recently, biomarker data from the SPARTAN interim analysis demonstrated sparsentan&#8217;s anti-inflammatory effect in humans, supporting data from early mouse models of IgA nephropathy that showed attenuation of immune and proinflammatory signaling with sparsentan.<sup>8,19,20<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-ocean-blue-color has-text-color has-link-color wp-elements-51cd0c4ef90fd47f09aee67a5374353a\" id=\"h-references\" style=\"margin-bottom:calc(30px * var(--scale))\"><strong>References<\/strong><\/h5>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list has-small-font-size\">\n<li class=\"has-small-font-size\">Kohan DE et al. <em>Clin Sci (Lond)<\/em>. 2024;138(11):645-662.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kohno M et al. <em>Kidney International<\/em>. 1992;42(4):860-866.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Chen L et al. <em>Hypertension<\/em>. 1995;26(1):83-88.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Komers R et al. <em>Am J Physiol Regul Integr Comp Physio<\/em>l. 2016;310(10):R877-884.<\/li>\n\n\n\n<li class=\"has-small-font-size\">R\u00fcster C et al. <em>J Am Soc Nephrol<\/em>. 2011;22(7):1189-1199.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kobori H et al. <em>Curr Pharm Des<\/em>. 2013;19(17):3033-3042.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Barton M et al. <em>Semin Nephrol<\/em>. 2015;35(2):156-167.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Nagasawa H et al. <em>Nephrol Dial Transplant<\/em>. 2024;39(9):1494-1503.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Saleh MA et al. <em>Hypertension<\/em>. 2010;56(5):942-949.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Sorokin A et al. <em>Am J Physiol Renal Physiol<\/em>. 2003;285(4):F579-F589.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rivedal M et al. <em>Kidney International<\/em>. 2024;105(4):717-730.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Gong S et al. <em>Front Immunol<\/em>. 2021;12:769802.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Villacorta J et al. <em>Clin Kidney J<\/em>. 2021;14(1):212-219.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Yoon S-Y et al. <em>BMC Nephrology<\/em>. 2024;25(1):142.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Li J et al. <em>Kidney International Reports<\/em>. 2024;9(10):3016-3026.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Wimbury D et al. <em>Kidney Int<\/em>. 2024;105(2):381-388.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Huang YJ et al. <em>Front Immunol<\/em>. 2022;13:935700.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Nielsen AJ et al. <em>Clin Chem Lab Med<\/em>. 2021;59(4):701-709.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Cheung CK et al. Presented at: American Society of Nephrology, 2024; October 23-27, 2024; San Diego, USA. FR-OR63.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Reily C et al. <em>Am J Physiol Renal Physiol<\/em>. 2024;326(5):F862-F875.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Jenkinson C et al. Poster presented at: ISN World Congress of Nephrology; April 12-15, 2019; Melbourne, Australia. SAT-010.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Jenkinson C et al. Presentation at: International Symposium on IgA nephropathy; September 27-29, 2018; Buenos Aires, Argentina.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Trachtman H et al. <em>Expert Rev Clin Immunol<\/em>. 2024;20(6):571-576.<\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right has-small-font-size\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\">MA-SP-25-0016 | April 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":4897,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":""},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[188],"study_type":[176],"resource_type":[208],"class_list":["post-5360","rkd-news","type-rkd-news","status-publish","has-post-thumbnail","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-spartan","study_type-clinical","resource_type-newsletter"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rare Kidney Disease News | Spotlight on u-sCD163<\/title>\n<meta name=\"description\" content=\"Learn more about the role of urinary soluble CD163 in IgA nephropathy and the biomarker findings from the SPARTAN interim analysis!\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exploring the Mechanism of Sparsentan in IgAN: Including a Spotlight on Urinary sCD163, a Key Marker of Inflammation\" \/>\n<meta property=\"og:description\" content=\"Learn more about the role of urinary soluble CD163 in IgA nephropathy and the biomarker findings from the SPARTAN interim analysis!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T13:09:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/\",\"name\":\"Rare Kidney Disease News | Spotlight on u-sCD163\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/tablets-sparsentan-chemical-structure_header.png\",\"datePublished\":\"2024-12-17T00:27:57+00:00\",\"dateModified\":\"2025-10-14T13:09:21+00:00\",\"description\":\"Learn more about the role of urinary soluble CD163 in IgA nephropathy and the biomarker findings from the SPARTAN interim analysis!\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/tablets-sparsentan-chemical-structure_header.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/tablets-sparsentan-chemical-structure_header.png\",\"width\":1920,\"height\":1080,\"caption\":\"Tablets and chemical structure of sparsentan\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/uscd163-inflammatory-biomarker-spartan-interim\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spotlight on u-sCD163\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rare Kidney Disease News | Spotlight on u-sCD163","description":"Learn more about the role of urinary soluble CD163 in IgA nephropathy and the biomarker findings from the SPARTAN interim analysis!","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Exploring the Mechanism of Sparsentan in IgAN: Including a Spotlight on Urinary sCD163, a Key Marker of Inflammation","og_description":"Learn more about the role of urinary soluble CD163 in IgA nephropathy and the biomarker findings from the SPARTAN interim analysis!","og_url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-14T13:09:21+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/","url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/","name":"Rare Kidney Disease News | Spotlight on u-sCD163","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header.png","datePublished":"2024-12-17T00:27:57+00:00","dateModified":"2025-10-14T13:09:21+00:00","description":"Learn more about the role of urinary soluble CD163 in IgA nephropathy and the biomarker findings from the SPARTAN interim analysis!","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/09\/tablets-sparsentan-chemical-structure_header.png","width":1920,"height":1080,"caption":"Tablets and chemical structure of sparsentan"},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/uscd163-inflammatory-biomarker-spartan-interim\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"Spotlight on u-sCD163"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 10:05:25","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"therapeutic_area","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/5360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/rkd-news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/4897"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=5360"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=5360"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=5360"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=5360"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=5360"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=5360"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=5360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}